Cite
MLA Citation
James A. Simon et al.. “Efficacy and safety of elinzanetant, a selective neurokinin-1, 3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).” Menopause, vol. 30, no. 3, 2023, pp. 239–246. http://access.bl.uk/ark:/81055/vdc_100179397543.0x000036